Power Metallic Mines A Copper Play for a Price Rally
Copper has recently outperformed gold and silver. Since October 2025, the price of this industrial metal has risen by about 50%. The main drivers are growing demand from the electrification, power grid, data center, and renewable energy sectors, as well as limited supply from new mines.
An interesting stock to profit from this trend is Power Metallic Mines. The stock has lost about 15% of its value this year and is currently trading at around CAD 1.10. In Germany, the security with ISIN CA73929R1055 is traded on Tradegate. Analysts at GBC Research recommend buying Power Metallic Mines with a price target of CAD 3.
The exploration company is developing what may be the world's most exciting multi-metal deposit in Canada: Nisk-Lion-Tiger. Most recently, the company reported the completion of the 2026 winter drilling program in the Lion Zone with further high-grade results. Of particular note is drill hole PML-26-116, which intersected a 36.42-meter-thick interval averaging 2.83% copper equivalent at a depth of only about 75 m. This included 6.00 m with an exceptionally high 12.38% copper equivalent. The near-surface location and high grades could be significant for potential future development via cost-effective open-pit mining.
The new data will be incorporated into the first NI 43-101-compliant mineral resource estimate for the Lion Zone. Completion is scheduled for the end of July. Power Metallic then plans to begin a preliminary economic assessment (PEA). At the same time, infill drilling improves the dataset for modeling the deposit, thereby increasing planning certainty for the next development steps of the Nisk-Lion-Tiger project.
Power Metallic also considers itself well-positioned at the corporate level. At the annual shareholders' meeting, shareholders approved an amendment to the articles of incorporation that enables the company to comply with the requirements of US stock exchanges. Management views a potential US listing as an opportunity to increase visibility among institutional and retail investors. Together with the high-grade polymetallic drill results, the good metallurgical recoveries, and the upcoming resource estimate, this could provide new momentum for the company's further development.
Power Metallic Mines: Why Did Investors Bet ≈ $30 Million? - YouTube
On the operational front, there was recently positive news from the US, among other developments. There, the company received a five-year follow-on contract from the Army Contracting Command – Detroit Arsenal to manufacture the HMPT-800 transmission. The framework agreement is already the fourth multi-year contract of this kind and could reach a maximum volume of up to USD 691 million. Since the start of the THOR partnership, the company has delivered more than 4,500 transmissions, thereby supporting the expansion and maintenance of the US Army's medium tracked vehicle fleet.
The HMPT transmission is used, among other vehicles, in the Bradley Fighting Vehicle and the Armored Multi-Purpose Vehicle. Renk America views the contract as confirmation of its long-standing manufacturing expertise and its role in ensuring the operational readiness of military vehicles. At its Muskegon facility, the company intends to continue providing reliable drive solutions and technical support for the US Army's ground combat vehicle fleet.
Eckert & Ziegler: 50% Upside Potential?
Eckert & Ziegler's chart currently offers no cause for optimism. For about a year, it has been following a textbook pattern, moving from the top-left to the bottom-right. During this period, the price fell from EUR 22 to just over EUR 13.
NuWays believes Eckert & Ziegler remains well-positioned in the structurally growing market for radiopharmaceuticals, despite the imminent market entry of competitor Curium. Of particular importance is the business with GalliaPharm, a gallium-68 generator that is estimated to contribute 20% to consolidated revenue. Demand is benefiting from the rapid growth of prostate theranostics. Rising treatment numbers with Novartis' Pluvicto are leading to more diagnostic examinations using gallium-68 PSMA-PET. Eckert & Ziegler currently holds an estimated market share of 60% to 80%.
With GalenVita, Curium is expected to launch a competing gallium-68 generator in the second half of 2026. NuWays therefore anticipates declining market share for Eckert & Ziegler but expects its absolute revenue to continue rising. Curium is likely to ramp up production only gradually due to operational requirements and is expected to capture around 30% of the market in the medium term. Since analysts estimate that the overall market could nearly double by 2030, Eckert & Ziegler's gallium-68 revenue is projected to rise from an estimated EUR 60 to 65 million in 2025 to around EUR 100 million in 2030.
In the short term, NuWays expects revenue to decline by about 4% to EUR 77 million in the second quarter, with adjusted EBIT of EUR 17.9 million. The operating margin is nevertheless expected to rise slightly to 23.3%. Additional growth momentum could come from the Lu-177 business if Lantheus brings the PNT2003 drug to market. Overall, NuWays considers the risk-reward ratio attractive, given the low valuation of approximately 8x expected 2026 EBITDA. The "Buy" recommendation is confirmed; however, the price target is lowered from EUR 23.00 to EUR 21.50 due to more conservative assumptions regarding the gallium-68 business. This implies an upside potential of around 50%.
Renk is a core investment in the European defense sector. However, the focus on "heavy military equipment" repeatedly raises concerns about the future. The CEO of Power Metallic Mines is not concerned about the future. In interviews, he has repeatedly expressed optimism about the company's potential. The coming months are likely to be exciting. Eckert & Ziegler operates in an attractive market, but the chart does not yet support buying the shares. Even so, the stock deserves a place on investors' watchlists.
